Histogenics has enrolled 123 (>50%) of the 245 patients required to complete enrollment in its ongoing NeoCart® Phase III clinical trial. This trial is being conducted under a Special Protocol Assessment with FDA.
Company leadership attributes its progress to enrollment-enhancing strategies implemented in 2015, as well as changes by FDA in 4Q15 to the Phase III clinical trial inclusion/exclusion criteria. Trial enrollment is expected to complete in 2Q17.
Histogenics has enrolled 123 (>50%) of the 245 patients required to complete enrollment in its ongoing NeoCart® Phase III clinical trial. This trial is being conducted under a Special Protocol Assessment with FDA.
Company leadership attributes its progress to enrollment-enhancing strategies implemented in 2015, as well as changes by FDA in...
Histogenics has enrolled 123 (>50%) of the 245 patients required to complete enrollment in its ongoing NeoCart® Phase III clinical trial. This trial is being conducted under a Special Protocol Assessment with FDA.
Company leadership attributes its progress to enrollment-enhancing strategies implemented in 2015, as well as changes by FDA in 4Q15 to the Phase III clinical trial inclusion/exclusion criteria. Trial enrollment is expected to complete in 2Q17.
Our site uses cookies to allow easier access for Members and subscribers and to improve our site. You agree to our use of cookies by closing this message box or continuing to use our site.OkRead more
Copy to clipboard 
